{"sent_idx": "169", "frame_idx": "20", "ev": "The study also showed that NSI-189 had significantly greater antidepressant effects than placebo in two (SDQ and CPFQ) of the four depression outcome measures.", "icos": [["1", "NSI - 189", "placebo", "antidepressant effects"]], "sample": "x"}
{"sent_idx": "11", "frame_idx": "0", "ev": "NSI-189 was relatively well tolerated at all doses, with no serious adverse effects.", "icos": [["0.9996014", "NSI - 189", "NSI - 189", "well tolerated"], ["0.9990085", "NSI - 189", "NSI - 189 phosphate", "well tolerated"], ["0.99854857", "NSI - 189", "NSI 189 phosphate", "well tolerated"], ["0.987793", "NSI - 189", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "well tolerated"], ["0.92658997", "NSI - 189", "placebo", "well tolerated"]], "sample": "c"}
{"sent_idx": "11", "frame_idx": "1", "ev": "NSI-189 was relatively well tolerated at all doses, with no serious adverse effects.", "icos": [["0.99964714", "NSI - 189", "NSI - 189", "serious adverse effects ."], ["0.99937445", "NSI - 189", "NSI - 189 phosphate", "serious adverse effects ."], ["0.9991373", "NSI - 189", "NSI 189 phosphate", "serious adverse effects ."], ["0.9138501", "NSI - 189", "placebo", "serious adverse effects ."], ["0.81302965", "NSI - 189", "antidepressant medication ( s )", "serious adverse effects ."]], "sample": "c"}
{"sent_idx": "46", "frame_idx": "7", "ev": "Prior Phase 1 clinical studies with doses of NSI-189 up to 80 mg as a single dose demonstrated no drug-related adverse events (Data on File, Neuralstem).", "icos": [["0.9985672", "NSI - 189", "NSI - 189", "adverse events"], ["0.14530785", "NSI - 189", "antidepressant medication", "adverse events"], ["0.118692115", "NSI - 189", "placebo", "adverse events"], ["0.03774687", "NSI - 189", "antidepressant medication ( s )", "adverse events"], ["0.010202234", "NSI - 189", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "adverse events"]], "sample": "c"}
{"sent_idx": "85", "frame_idx": "10", "ev": "There was no difference in the frequency of blood draws between placebo and active subjects.", "icos": [["0.8014055", "placebo", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "frequency of blood draws"], ["0.43517515", "placebo", "NSI - 189", "frequency of blood draws"], ["0.2269397", "placebo", "antidepressant medication", "frequency of blood draws"], ["0.17278081", "placebo", "antidepressant medication ( s )", "frequency of blood draws"], ["0.10488087", "placebo", "placebo", "frequency of blood draws"]], "sample": "c"}
{"sent_idx": "121", "frame_idx": "11", "ev": "With respect to the primary aim of the study, NSI-189 was well tolerated supporting the dose escalation up to 40 mg t.i.d.", "icos": [["0.99948114", "NSI - 189", "NSI - 189", "tolerated"], ["0.98455286", "NSI - 189", "antidepressant medication ( s )", "tolerated"], ["0.9773934", "NSI - 189", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "tolerated"], ["0.96277714", "NSI - 189", "antidepressant medication", "tolerated"], ["0.88640285", "NSI - 189", "NSI - 189 phosphate", "tolerated"]], "sample": "c"}
{"sent_idx": "139", "frame_idx": "12", "ev": "There was a significantly greater reduction in depressive symptoms at day 28 (the end of the double-blind phase) in the pooled NSI-189 patients compared with the placebo-treated patients on the SDQ.", "icos": [["0.99413353", "placebo", "NSI - 189", "depressive symptoms"], ["0.9925178", "placebo", "NSI - 189 phosphate", "depressive symptoms"], ["0.98501694", "placebo", "antidepressant medication ( s )", "depressive symptoms"], ["0.984513", "placebo", "antidepressant medication", "depressive symptoms"], ["0.9811863", "placebo", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "depressive symptoms"]], "sample": "c"}
{"sent_idx": "145", "frame_idx": "15", "ev": "Figure 5d demonstrates the significant reduction in symptoms on the CPFQ at day 28 in the pooled NSI-189 patients compared with the placebo-treated patients, maintained until the end of the follow-up period.", "icos": [["0.9954796", "placebo", "NSI - 189 phosphate", "symptoms"], ["0.98920655", "placebo", "NSI - 189", "symptoms"], ["0.9862882", "placebo", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "symptoms"], ["0.9803452", "placebo", "antidepressant medication", "symptoms"], ["0.9791794", "placebo", "antidepressant medication ( s )", "symptoms"]], "sample": "c"}
{"sent_idx": "148", "frame_idx": "16", "ev": "Analysis of covariance results did not show significant differences in hippocampal volume at day 28 (left: F(1,21)=0.06, P=0.80; right: F(1,21)=0.71, P=0.41) or day 84 (left: F(1,18)=1.25, P=0.28; right: F(1,18)=4.17, P=0.06) between the pooled NSI-189 and placebo-treated patients.", "icos": [["0.9955279", "placebo", "NSI - 189", "hippocampal volume"], ["0.96342754", "placebo", "placebo", "hippocampal volume"], ["0.9610104", "placebo", "NSI 189 phosphate", "hippocampal volume"], ["0.28269204", "placebo", "NSI - 189 phosphate", "hippocampal volume"], ["0.016423725", "placebo", "antidepressant medication ( s )", "hippocampal volume"]], "sample": "c"}
{"sent_idx": "150", "frame_idx": "17", "ev": "The post hoc repeated measures analysis of variance suggested a modest but not statistically significant increase in the left hippocampal volume in the NSI-189-treated patients (b=0.35, P=0.12), but not the right side (right: b=\u22120.03, P=0.82).", "icos": [["0.9995441", "NSI - 189", "NSI - 189", "left hippocampal volume"], ["0.99858296", "NSI - 189", "NSI - 189 phosphate", "left hippocampal volume"], ["0.9984829", "NSI - 189", "NSI 189 phosphate", "left hippocampal volume"], ["0.9967193", "NSI - 189", "sagittal T1 - weighted , three - dimensional , non - contrast enhanced , inversion recovery high - resolution spiral imaging ( IR - SPGR ) sequence", "left hippocampal volume"], ["0.98346275", "NSI - 189", "antidepressant medication ( s )", "left hippocampal volume"]], "sample": "c"}
{"sent_idx": "158", "frame_idx": "18", "ev": "Using baseline plasma levels of brain-derived neurotrophic factor, epidermal growth factor, myeloperoxidase, tumor necrosis factor receptor type 2 and A1AT, the model, with one exception (patient 608), was able to identify the response to NSI-189, in 17 out of 18 cases that are consistent with therapeutic effects shown by the decrement in MADRS score.", "icos": [["0.999263", "NSI - 189", "NSI - 189", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT"], ["0.87673545", "NSI - 189", "NSI 189 phosphate", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT"], ["0.85761577", "NSI - 189", "antidepressant medication ( s )", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT"], ["0.5292359", "NSI - 189", "NSI - 189 phosphate", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT"], ["0.111615926", "NSI - 189", "antidepressant medication", "plasma levels of brain - derived neurotrophic factor , epidermal growth factor , myeloperoxidase , tumor necrosis factor receptor type 2 and A1AT"]], "sample": "c"}
